Shanghai Genechem Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Private, Subsidiary
- Established
- 2013-09-22
- Employees
- 251
- Market Cap
- -
- Website
- https://www.genechem.com.cn
A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03130712
- Locations
- 🇨🇳
302 Military Hospital, Beijing, China
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
Phase 1
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: anti-CD19-CAR-T cells
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT03030976
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Phase 1
- Conditions
- Colorectal Cancer MetastaticCarcinoma, HepatocellularPancreatic Cancer Metastatic
- Interventions
- Drug: CAR-T cell
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02959151
- Locations
- 🇨🇳
Shanghai Tumor Hospital, Shanghai, Shanghai, China
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Phase 1
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: TAI-GPC3-CART cells
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02715362
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Phase 1
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: TAI-meso-CART
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02706782
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Phase 1
- Conditions
- Leukemia, B-Cell
- Interventions
- Drug: anti-CD19-CAR-T cells
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02672501
- Locations
- 🇨🇳
Shanghai Changhai Hospital，The Second Military Medical University, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath